PrP106-126 and Aβ1-42 Peptides Induce BV-2 Microglia Chemotaxis and Proliferation

Transmissible spongiform encephalopathies (TSEs) and Alzheimer's disease (AD) belong to a growing family of neurodegenerative disorders that is characterized by the generation of toxic protein aggregates in affected brains (PrPSc and Aβ in TSEs and AD, respectively). To better understand how protein aggregates can modulate microglial processes in these diseases, we treated BV-2 microglia with PrP106-126 or Aβ1-42 peptides individually at three different concentrations (25–100 μM PrP106-12 and 2.5–10 μM Aβ1-42) or with a mixture of PrP106-126 and Aβ1-42 peptides at specified concentrations for 6–24 h. BV-2 microglia chemotaxis, proliferation, and monocyte chemoattractant protein-1 and transforming growth factor-β1 (TGF-β1) secretion were measured and compared between treatments. The results demonstrate that PrP106-126 and Aβ1-42 peptides induce increases in all four parameters from 6 to 12 h. However, the measured indices plateaued beyond 12 h in BV-2 cells treated >50 μM PrP or >5 μM Aβ1-42, with the exception of TGF-β1 secretion, which continued to increase gradually. Overall, the results of this study indicate that these two peptides may mutually inhibit microglial chemotaxis and proliferation simultaneously via changes induced at the protein level.